CA2540501C - Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci - Google Patents

Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci Download PDF

Info

Publication number
CA2540501C
CA2540501C CA2540501A CA2540501A CA2540501C CA 2540501 C CA2540501 C CA 2540501C CA 2540501 A CA2540501 A CA 2540501A CA 2540501 A CA2540501 A CA 2540501A CA 2540501 C CA2540501 C CA 2540501C
Authority
CA
Canada
Prior art keywords
group
alkyl
ylcarbonyl
substituted
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2540501A
Other languages
English (en)
Other versions
CA2540501A1 (fr
Inventor
Frank Himmelsbach
Birgit Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CA2540501A1 publication Critical patent/CA2540501A1/fr
Application granted granted Critical
Publication of CA2540501C publication Critical patent/CA2540501C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2540501A 2003-09-30 2004-09-24 Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci Expired - Fee Related CA2540501C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEDE10345875.1 2003-09-30
DE10345875A DE10345875A1 (de) 2003-09-30 2003-09-30 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
PCT/EP2004/010723 WO2005033096A1 (fr) 2003-09-30 2004-09-24 Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci

Publications (2)

Publication Number Publication Date
CA2540501A1 CA2540501A1 (fr) 2005-04-14
CA2540501C true CA2540501C (fr) 2012-05-22

Family

ID=34353273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2540501A Expired - Fee Related CA2540501C (fr) 2003-09-30 2004-09-24 Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci

Country Status (5)

Country Link
EP (1) EP1670781A1 (fr)
JP (1) JP2007507445A (fr)
CA (1) CA2540501C (fr)
DE (1) DE10345875A1 (fr)
WO (1) WO2005033096A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01012899A (es) 1999-06-21 2002-07-30 Boehringer Ingelheim Pharma Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
EP3173084B1 (fr) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Dérivés de quinazoline pour le traitement de cancers
EP2065369A4 (fr) * 2006-08-23 2011-12-28 Astellas Pharma Inc Compose d'uree ou sel dudit compose
CA2663599A1 (fr) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Procede de traitement du cancer presentant des mutations egfr
EP2451445B1 (fr) 2009-07-06 2019-04-03 Boehringer Ingelheim International GmbH Procédé de séchage du bibw2992, de ses sels et des préparations pharmaceutiques solides contenant ce principe actif
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0892789B2 (fr) * 1996-04-12 2009-11-18 Warner-Lambert Company LLC Inhibiteurs irreversibles de tyrosine kinases
BR0008524A (pt) * 1999-02-27 2001-12-18 Boehringer Ingelheim Pharma Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
MXPA01012899A (es) * 1999-06-21 2002-07-30 Boehringer Ingelheim Pharma Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
US7001904B1 (en) * 2000-06-24 2006-02-21 Astrazeneca Ab Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU2002210714A1 (en) * 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
KR101064530B1 (ko) * 2002-03-30 2011-09-14 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 티로신 키나아제 억제제로서의 4-(ｎ-페닐아미노)-퀴나졸린/퀴놀린, 이를 함유하는 약제학적 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
JP2007507445A (ja) 2007-03-29
EP1670781A1 (fr) 2006-06-21
DE10345875A1 (de) 2005-04-21
CA2540501A1 (fr) 2005-04-14
WO2005033096A1 (fr) 2005-04-14

Similar Documents

Publication Publication Date Title
US7456189B2 (en) Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
CA2476008C (fr) Composes heterocyclique bicyclique, compositions pharmaceutiques contenat ces composes, leur utilisation et procede de preparation
US6924285B2 (en) Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20020082270A1 (en) Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
TW200302221A (en) Quinazoline derivatives
US20110136806A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
CA2484395C (fr) Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de production
US20070185081A1 (en) Bicyclic heterocylces, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US20090036474A1 (en) Quinazoline derivatives for use against cancer
AU2004213129A1 (en) Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
CA2417042A1 (fr) Heterocycles bicycliques, medicaments contenant lesdits composes, leur utilisation et procedes permettant de les produire
CA2540501C (fr) Derives de quinoleine et de quinazoline, medicaments contenant ces composes, utilisation et procede de production de ceux-ci
US20090036485A1 (en) Quinoline derivatives
EP2298305A1 (fr) 4-(N-Phenylamino)-quinazolines/quinoline en tant qu'inhibiteurs de tyrosine kinases
JP2007507445A6 (ja) キノリン及びキナゾリン誘導体、これを含む薬物、その使用及びその調製方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130924